Cell structure and method for producing same

Abstract

The present invention pertains to a cell structure comprising a connective tissue structure and an epithelial structure positioned on the connective tissue structure, the cell structure being such that the connective tissue structure includes a fragmented extracellular matrix component and first cells that include mesenchymal cells, at least a portion of the fragmented extracellular matrix component is positioned between the first cells, and the epithelial structure includes epithelial cells.

Description

[Technical field]

[0001] The present invention also relates to a bacteria-containing tissue model and a method for producing the same, and a method for evaluating the behavior of the cell structure and / or bacteria. [Background technology]

[0002] As a method for artificially producing a structure that mimics a living tissue, for example, a method for producing a three-dimensional tissue (Patent Document 1) including arranging cells coated with a membrane containing collagen in three dimensions to form a three-dimensional tissue, and a method for producing a three-dimensional cell tissue (Patent Document 2) including mixing cells with a cationic substance and an extracellular matrix component to obtain a mixture, collecting cells from the obtained mixture, and forming a cell aggregate on a substrate are known. In addition, the present inventors have proposed a method for producing a large-sized three-dimensional tissue with a thickness of 1 mm or more with a relatively small number of cells by contacting cells with fragmented exogenous collagen (Patent Document 3). Such three-dimensional tissues are expected to be used as substitutes for laboratory animals, transplant materials, etc. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] International Publication No. 2015 / 072164 [Patent Document 2] International Publication No. 2017 / 146124 [Patent Document 3] International Publication No. 2018 / 143286 Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide a cell structure that is closer to living tissue and a method for producing the same. [Means for solving the problem]

[0005] That is, the present invention relates to, for example, the following inventions. [1] A cell structure comprising a connective tissue structure and an epithelial structure disposed on the connective tissue structure, wherein the connective tissue structure comprises fragmented extracellular matrix components and first cells comprising mesenchymal cells, at least a portion of the fragmented extracellular matrix components being disposed between the first cells, and the epithelial structure comprises epithelial cells. [2] The cell structure described in [1], wherein the mesenchymal cells include fibroblasts. [3] The cell structure described in [1] or [2], wherein the fragmented extracellular matrix component comprises a fragmented collagen component. [4] The cell structure described in any one of [1] to [3], wherein the first cells further contain vascular endothelial cells, and the connective tissue structure has a vascular network between the cells. [5] The cell structure described in [4], wherein the connective tissue structure has a vascular network between the mesenchymal cells. [6] A bacteria-containing tissue model comprising a cell structure according to any one of [1] to [5] and bacteria arranged inside the cell structure or in contact with an epithelial structure of the cell structure. [7] The bacteria-containing tissue model described in [6], in which the bacteria are periodontal pathogens. [8] A method for producing a cell structure, comprising: a first step of forming a connective tissue structure by contacting fragmented extracellular matrix components with first cells, including mesenchymal cells, and culturing the first cells; and a second step of contacting the connective tissue structure with second cells, including epithelial cells, and culturing the connective tissue structure and the second cells, thereby forming an epithelial structure on the connective tissue structure to obtain a cell structure. [9] The method for producing a cell structure described in [8], wherein the first cell includes a vascular endothelial cell.

[10] The amount of fragmented extracellular matrix components contacted with the first cells is 1.0 × 10 6 The method for producing a cell structure according to [8] or [9], wherein the amount of the cell structure is 0.1 to 100 mg per 100 cells.

[11] A method for producing a bacteria-containing tissue model, comprising a step of contacting bacteria with an epithelial structure of a cell structure obtained by the production method according to any one of [8] to

[10] .

[12] A method for producing a bacteria-containing tissue model described in

[11] , comprising, after the step of contacting the bacteria, a step of culturing the cell structure and the bacteria and transferring the bacteria to the inside of the cell structure.

[13] A method for evaluating the behavior of a cell structure and / or bacteria, comprising the steps of contacting bacteria with an epithelial structure of a cell structure described in any one of [1] to [5] and then evaluating the behavior of the cell structure and / or bacteria. Effect of the Invention

[0006] According to the present invention, it is possible to provide a cell structure that is closer to living tissue and a method for producing the same. [Brief description of the drawings]

[0007] [Figure 1] Photographs showing the results of microscopic observation of cell structures stained with hematoxylin and eosin (HE). [Diagram 2] Photographs showing the formation of a vascular network in connective tissue in a cell structure. [Diagram 3] Photographs showing the results of confirming the survival and invasion of periodontal disease bacteria (Image Analysis). [Figure 4] Photographs showing the results of confirming the engraftment and invasion of P. gingivalis into a cell structure having a vascular network. [Diagram 5] 1 is a graph showing the results of quantitative evaluation of P. gingivalis co-localized with the vascular network. [Figure 6] 1 is a graph showing the results of quantitative evaluation of the number of P. gingivalis that had invaded into model gingival tissue. [Figure 7] 1 is a graph showing the results of evaluating the amount of IL-6 secreted after infection with P. gingivalis. [Figure 8] FIG. 1 shows a method for evaluating the behavior of P. gingivalis penetrating epithelial structures. [Figure 9]1 is a graph showing the results of evaluating the behavior of P. gingivalis penetrating epithelial structures. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Hereinafter, an embodiment of the present invention will be described in detail. However, the present invention is not limited to the following embodiment.

[0009] <Cell structure> The cell structure according to this embodiment includes a connective tissue structure and an epithelial structure disposed on the connective tissue structure. In the cell structure according to this embodiment, the connective tissue structure includes fragmented extracellular matrix components and first cells including mesenchymal cells, and at least a portion of the fragmented extracellular matrix components is disposed between the first cells. In the cell structure according to this embodiment, the epithelial structure includes epithelial cells.

[0010] The cell structure can be used, for example, as a biological tissue model. Specific examples of the biological tissue model include a gingival model, an oral mucosa model, a skin model, and a cornea model.

[0011] As used herein, the term "cell structure" refers to an assembly of cells in which cells are arranged three-dimensionally via extracellular matrix components, and is an assembly artificially produced by cell culture. The shape of the cell structure is not particularly limited, and examples of the shape include a sheet, a sphere, an ellipsoid, and a rectangular parallelepiped. Here, biological tissue includes sweat glands, lymphatic vessels, sebaceous glands, etc., and has a more complex structure than a cell structure. Therefore, cell structures and biological tissues can be easily distinguished.

[0012] (cell) As used herein, the term "cell" is not particularly limited, and may be, for example, a cell derived from a mammal such as a human, monkey, dog, cat, rabbit, pig, cow, mouse, or rat. The site of origin of the cell is also not particularly limited, and may be a somatic cell derived from bone, muscle, internal organs, nerve, brain, bone, skin, blood, or the like, or may be a germ cell. Furthermore, the cell may be a stem cell, or may be a cultured cell such as a primary cultured cell, a subcultured cell, or a cell line cell.

[0013] As used herein, the term "stem cell" refers to a cell that has self-renewal and pluripotency. Stem cells include pluripotent stem cells capable of differentiating into any cell type, and tissue stem cells (also called somatic stem cells) capable of differentiating into a specific cell type. Examples of pluripotent stem cells include embryonic stem cells (ES cells), somatic cell-derived ES cells (ntES cells), and induced pluripotent stem cells (iPS cells). Examples of tissue stem cells include mesenchymal stem cells (e.g., adipose stem cells, bone marrow-derived stem cells), hematopoietic stem cells, and neural stem cells. Examples of adipose stem cells include human adipose stem cells (ADSCs).

[0014] The cell structure may have a survival rate of 70% or more, 80% or more, or 90% or more after trypsin treatment at a trypsin concentration of 0.25%, at a temperature of 37°C, pH 7.4, and for a reaction time of 15 minutes. Such a cell structure is unlikely to be decomposed by enzymes during or after culture, and is stable. The survival rate can be calculated, for example, from the mass of the cell structure before and after trypsin treatment.

[0015] The cell structure may have a survival rate of 70% or more, 80% or more, or 90% or more after collagenase treatment at a collagenase concentration of 0.25%, at a temperature of 37° C., at pH 7.4, and for a reaction time of 15 minutes. Such a cell structure is unlikely to be decomposed by enzymes during or after culture, and is stable.

[0016] The thickness of the cell structure is preferably 10 μm or more, more preferably 100 μm or more, and even more preferably 1000 μm or more. Such a cell structure has a structure closer to that of living tissue, and is suitable as a substitute for laboratory animals and as a transplant material. The upper limit of the thickness of the cell structure is not particularly limited, and may be, for example, 10 mm or less, 3 mm or less, 2 mm or less, 1.5 mm or less, or 1 mm or less.

[0017] Here, the "thickness of the cell structure" means the distance between both ends in the direction perpendicular to the main surface when the cell structure is sheet-shaped or rectangular. When the main surface has irregularities, the thickness means the distance at the thinnest part of the main surface.

[0018] When the cell structure is spherical, the thickness means its diameter. When the cell structure is ellipsoidal, the thickness means its minor axis. When the cell structure is approximately spherical or approximately ellipsoidal and has an uneven surface, the thickness means the shortest distance between two points where a line passing through the center of gravity of the cell structure intersects with the surface.

[0019] [Connective tissue structure] The connective tissue structure includes a fragmented extracellular matrix component and a first cell. At least a portion of the fragmented extracellular matrix component is disposed between the first cells. By using the fragmented extracellular matrix component in the cell structure, it is possible to form a connective tissue structure that includes a higher density of extracellular matrix molecules, which facilitates the formation of a thicker connective tissue structure.

[0020] (Fragmented extracellular matrix components) In the present specification, the term "extracellular matrix component" refers to an assembly of extracellular matrix molecules formed by a plurality of extracellular matrix molecules. The extracellular matrix refers to a substance that exists outside cells in an organism. Any substance can be used as the extracellular matrix as long as it does not adversely affect cell growth and cell aggregate formation. Specific examples include, but are not limited to, collagen, elastin, proteoglycan, fibronectin, hyaluronic acid, laminin, vitronectin, tenascin, entactin, and fibrillin. The extracellular matrix component may be used alone or in combination. The extracellular matrix component may, for example, contain a collagen component or may be a collagen component. The extracellular matrix component in this embodiment is preferably a substance that exists outside animal cells, that is, an animal extracellular matrix component. In addition, the extracellular matrix molecule may be a modified or variant of the above-mentioned extracellular matrix molecule, or may be a polypeptide such as a chemically synthesized peptide, as long as it does not adversely affect cell growth and cell aggregate formation.

[0021] "Fragmentation" refers to breaking down an aggregate of an extracellular matrix component into smaller sizes. The fragmented extracellular matrix component may include a defibrated extracellular matrix component. The defibrated extracellular matrix component is a component obtained by defibrating the above-mentioned extracellular matrix component by application of a physical force. For example, defibration is performed under conditions that do not break the bonds within the extracellular matrix molecules.

[0022] The shape of the fragmented extracellular matrix component may be any shape. Specific examples include, but are not limited to, fibrous, spindle-shaped, amorphous, spherical, granular, powdery, flat, and sheet-shaped. The shape is preferably the same as or similar to the shape of the extracellular matrix component in the organism. For example, when the extracellular matrix component is collagen, it is preferably fibrous.

[0023] The method for fragmenting the extracellular matrix components such as collagen components is not particularly limited, and may be fragmented by applying a physical force. The method for fragmenting the extracellular matrix components may be, for example, a method for finely breaking down the clumped extracellular matrix components. The extracellular matrix components may be fragmented as they are. That is, the extracellular matrix components may be fragmented in a solid phase. The extracellular matrix components may also be fragmented in an aqueous medium. The fragmentation of the extracellular matrix components by applying a physical force can be performed using, for example, an ultrasonic homogenizer, an agitation homogenizer, a high-pressure homogenizer, or the like. When using an agitation homogenizer, the extracellular matrix components may be homogenized as they are, or may be homogenized in an aqueous medium such as physiological saline. It is also possible to obtain fragmented extracellular matrix components of millimeter size or nanometer size by adjusting the homogenization time, number of times, etc.

[0024] The size of the fragmented extracellular matrix component can be determined, for example, by analyzing each fragmented extracellular matrix component using an electron microscope. The size of a fibrous fragmented extracellular matrix component may be the length in the longitudinal direction, and for fragmented extracellular matrix components having shapes other than fibrous, the size may be the maximum length of a straight line connecting one end and the other end of the fragmented extracellular matrix component.

[0025] The average size of the fragmented extracellular matrix components may be 100 nm or more and 400 μm or less, or 100 nm or more and 200 μm or less. In one embodiment, the average size of the fragmented extracellular matrix components may be 5 μm or more and 400 μm or less, 10 μm or more and 400 μm or less, or 100 μm or more and 400 μm or less, from the viewpoint of facilitating the formation of thick tissue. In another embodiment, the average size of the fragmented extracellular matrix components may be 100 μm or less, 50 μm or less, 30 μm or less, 15 μm or less, 10 μm or less, 1 μm or less, or 100 nm or more. It is preferable that the average size of the majority of the fragmented extracellular matrix components among all the fragmented extracellular matrix components is within the above numerical range. Specifically, of all the fragmented extracellular matrix components, it is preferred that the average size of 50% or more of the fragmented extracellular matrix components is within the above-mentioned range, and it is even more preferred that the average size of 95% of the fragmented extracellular matrix components is within the above-mentioned range. The fragmented extracellular matrix components are preferably fragmented collagen components having an average size within the above-mentioned range.

[0026] The average length of the fragmented extracellular matrix components may be 100 nm or more and 400 μm or less, or 100 nm or more and 200 μm or less. In one embodiment, the average length of the fragmented extracellular matrix components may be 5 μm or more and 400 μm or less, 10 μm or more and 400 μm or less, or 100 μm or more and 400 μm or less, from the viewpoint of facilitating the formation of thick tissue. In another embodiment, the average length of the fragmented extracellular matrix components may be 100 μm or less, 50 μm or less, 30 μm or less, 15 μm or less, 10 μm or less, 1 μm or less, or 100 nm or more. It is preferable that the average length of the majority of the fragmented extracellular matrix components among all the fragmented extracellular matrix components is within the above numerical range. Specifically, it is preferable that the average length of 50% or more of the fragmented extracellular matrix components is within the above-mentioned range, and it is more preferable that the average length of 95% of the fragmented extracellular matrix components is within the above-mentioned range. The fragmented extracellular matrix components are preferably fragmented collagen components having an average length within the above-mentioned range.

[0027] The average diameter of the fragmented extracellular matrix component may be 50 nm to 30 μm, 4 μm to 30 μm, or 5 μm to 30 μm. The fragmented extracellular matrix component is preferably a fragmented collagen component having an average diameter within the above range.

[0028] The average length and average diameter of the fragmented extracellular matrix components can be determined by measuring each fragmented extracellular matrix component using an optical microscope or the like and analyzing the images. In this specification, "average length" means the average value of the length in the longitudinal direction of the measured sample, and "average diameter" means the average value of the length in the direction perpendicular to the longitudinal direction of the measured sample.

[0029] When the extracellular matrix component is a collagen component, the fragmented extracellular matrix component is also called a "fragmented collagen component." The "fragmented collagen component" refers to a collagen component, such as a fibrous collagen component, that is fragmented and maintains a triple helix structure. The average length of the fragmented collagen component is preferably 100 nm to 200 μm, more preferably 22 μm to 200 μm, and even more preferably 100 μm to 200 μm. The average diameter of the fragmented collagen component is preferably 50 nm to 30 μm, more preferably 4 μm to 30 μm, and even more preferably 20 μm to 30 μm.

[0030] At least a portion of the fragmented extracellular matrix components may be intermolecularly or intramolecularly crosslinked. The extracellular matrix components may be crosslinked intramolecularly or intermolecularly among the extracellular matrix molecules that make up the extracellular matrix components.

[0031] Examples of the crosslinking method include physical crosslinking by applying heat, ultraviolet light, radiation, etc., and chemical crosslinking by a crosslinking agent, enzyme reaction, etc., but the method is not particularly limited. From the viewpoint of not interfering with cell growth, physical crosslinking is preferred. Crosslinking (physical crosslinking and chemical crosslinking) may be crosslinking via a covalent bond.

[0032] When the extracellular matrix component includes a collagen component, crosslinks may be formed between collagen molecules (triple helix structure) or between collagen fibrils formed by collagen molecules. Crosslinks may be thermal crosslinks (thermal crosslinks). Thermal crosslinks can be performed, for example, by heating under reduced pressure using a vacuum pump. When thermal crosslinking of collagen components is performed, the extracellular matrix component may be crosslinked by forming a peptide bond (-NH-CO-) between an amino group of a collagen molecule and a carboxy group of the same or another collagen molecule.

[0033] The extracellular matrix components can also be crosslinked by using a crosslinking agent. The crosslinking agent may be, for example, one capable of crosslinking a carboxyl group with an amino group, or one capable of crosslinking amino groups with each other. As the crosslinking agent, for example, aldehyde-based, carbodiimide-based, epoxide-based, and imidazole-based crosslinking agents are preferable from the viewpoints of economy, safety, and operability. Specific examples of the crosslinking agent include water-soluble carbodiimides such as glutaraldehyde, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide sulfonate.

[0034] The degree of crosslinking can be determined appropriately depending on the type of extracellular matrix component, the means of crosslinking, etc. The degree of crosslinking may be 1% or more, 2% or more, 4% or more, 8% or more, or 12% or more, and may be 30% or less, 20% or less, or 15% or less. When the degree of crosslinking is within the above range, the extracellular matrix molecules can be appropriately dispersed, and the redispersibility after dry storage is good.

[0035] When amino groups in the extracellular matrix components are used for crosslinking, the degree of crosslinking can be quantified based on the TNBS (2,4,6-trinitrobenzenesulfonic acid) method described in Acta Biomaterialia, 2015, vol. 25, pp. 131-142, etc. The degree of crosslinking by the TNBS method may be within the above-mentioned range. The degree of crosslinking by the TNBS method is the ratio of amino groups used for crosslinking among the amino groups in the extracellular matrix. When the extracellular matrix components include collagen components, it is preferable that the degree of crosslinking measured by the TNBS method is within the above-mentioned range.

[0036] The degree of crosslinking may be calculated by quantifying the carboxyl groups. For example, in the case of a water-insoluble extracellular matrix component, the degree of crosslinking may be quantified by the TBO (toluidine blue O) method. The degree of crosslinking by the TBO method may be within the above-mentioned range.

[0037] The content of extracellular matrix components in the cell structure may be 0.01 to 90 mass%, preferably 10 to 90 mass%, preferably 10 to 80 mass%, preferably 10 to 70 mass%, preferably 10 to 60 mass%, preferably 1 to 50 mass%, preferably 10 to 50 mass%, more preferably 10 to 30 mass%, and more preferably 20 to 30 mass%, based on the dry weight of the connective tissue structure.

[0038] Here, "extracellular matrix components in a cell structure" means extracellular matrix components that constitute the cell structure, and may be derived from endogenous extracellular matrix components or exogenous extracellular matrix components.

[0039] "Endogenous extracellular matrix components" refers to extracellular matrix components produced by extracellular matrix-producing cells. Examples of extracellular matrix-producing cells include the above-mentioned mesenchymal cells such as fibroblasts, chondrocytes, and osteoblasts. Endogenous extracellular matrix components may be fibrous or non-fibrous.

[0040] "Exogenous extracellular matrix components" refers to extracellular matrix components supplied from the outside. The cell structure according to this embodiment contains fragmented extracellular matrix components, which are exogenous extracellular matrix components. The exogenous extracellular matrix components may originate from the same or different animal species as the endogenous extracellular matrix components. Examples of the animal species from which the exogenous extracellular matrix components originate include humans, pigs, and cows. The exogenous extracellular matrix components may also be artificial extracellular matrix components.

[0041] When the extracellular matrix component is a collagen component, the exogenous extracellular matrix component is also called an "exogenous collagen component", and the "exogenous collagen component" means a collagen component supplied from the outside, which is an aggregate of collagen molecules formed by a plurality of collagen molecules, and specifically includes fibrous collagen, non-fibrous collagen, etc. The exogenous collagen component is preferably fibrous collagen. The fibrous collagen means a collagen component that is the main component of collagen fibers, and examples thereof include type I collagen, type II collagen, and type III collagen. The fibrous collagen may be a commercially available collagen, and a specific example thereof is type I collagen derived from pig skin manufactured by Nippon Ham Co., Ltd. An example of an exogenous non-fibrous collagen is type IV collagen.

[0042] The exogenous extracellular matrix component may be derived from an animal species different from that of the cells. Also, when the cells include extracellular matrix-producing cells, the exogenous extracellular matrix component may be derived from an animal species different from that of the extracellular matrix-producing cells. That is, the exogenous extracellular matrix component may be a xenogeneic extracellular matrix component.

[0043] That is, when a cell structure contains endogenous extracellular matrix components and fragmented extracellular matrix components, the content of extracellular matrix components constituting the cell structure means the total amount of the endogenous extracellular matrix components and the fragmented extracellular matrix components. The content of the extracellular matrix can be calculated from the volume of the obtained cell structure and the mass of the decellularized cell structure.

[0044] For example, when the extracellular matrix component contained in the cell structure is a collagen component, a method for quantifying the collagen component in the cell structure includes, for example, the following method for quantifying hydroxyproline. A lysis solution in which the cell structure is dissolved is mixed with hydrochloric acid (HCl), incubated at high temperature for a predetermined time, returned to room temperature, centrifuged, and the supernatant is diluted to a predetermined concentration to prepare a sample. A hydroxyproline standard solution is treated in the same manner as the sample, and then diluted stepwise to prepare a standard. Each of the sample and the standard is treated as specified with a hydroxyproline assay buffer and a detection reagent, and the absorbance at 570 nm is measured. The amount of collagen component is calculated by comparing the absorbance of the sample with the standard. The cell structure may be directly suspended in high-concentration hydrochloric acid, the lysis solution is centrifuged, and the supernatant is collected and used for collagen component quantification. The cell structure to be dissolved may be in the state as it is recovered from the culture solution, or may be dissolved in a state in which the liquid components are removed by drying after recovery. However, when quantifying collagen components by dissolving cell structures in the state recovered from the culture medium, it is expected that the measured weight of the cell structure will vary due to the influence of medium components absorbed by the cell structure and residual medium due to problems with the experimental technique. Therefore, from the viewpoint of stably measuring the weight of the tissue and the amount of collagen components per unit weight, it is preferable to use the weight after drying as the basis.

[0045] More specifically, the method for quantifying the amount of collagen component may be, for example, the following method. (Sample preparation) The entire amount of the freeze-dried cell structure is mixed with 6 mol / L HCl, incubated at 95°C in a heat block for more than 20 hours, and then returned to room temperature. After centrifugation at 13,000g for 10 minutes, the supernatant of the sample solution is collected. After diluting appropriately with 6 mol / L HCl so that the results fall within the range of the calibration curve in the measurement described below, the sample is prepared by diluting 200 μL with 100 μL of ultrapure water. 35 μL of sample is used.

[0046] (Preparation of standards) Add 125μL of standard solution (1200μg / mL in acetic acid) and 125μL of 12mol / l HCl to a screw-cap tube, mix, incubate in a heat block at 95℃ for 20 hours, then return to room temperature. After centrifugation at 13000g for 10 minutes, dilute the supernatant with ultrapure water to make S1 at 300μg / mL, and gradually dilute S1 to make S2 ​​(200μg / mL), S3 (100μg / mL), S4 (50μg / mL), S5 (25μg / mL), S6 (12.5μg / mL), and S7 (6.25μg / mL). Also prepare S8 (0μg / mL) containing only 90μL of 4mol / l HCl.

[0047] Assay Add 35 μL of each standard and sample to the plate (included in the QuickZyme Total Collagen Assay kit, QuickZyme Biosciences). Add 75 μL of assay buffer (included in the above kit) to each well. Seal the plate and incubate at room temperature for 20 minutes with shaking. Remove the seal and add 75 μL of detection reagent (reagent A:B=30 μL:45 μL, included in the above kit) to each well. Seal the plate, mix the solution by shaking, and incubate at 60°C for 60 minutes. Cool thoroughly on ice, remove the seal, and measure the absorbance at 570 nm. The amount of collagen components is calculated by comparing the absorbance of the sample with the standard.

[0048] The collagen component in the cell structure may be defined by its area ratio or volume ratio. "Defining by area ratio or volume ratio" means, for example, making the collagen component in the cell structure distinguishable from other tissue components by a known staining method (e.g., immunostaining with an anti-collagen antibody or Masson's trichrome staining), and then calculating the ratio of the area in the entire cell structure where the collagen component is present, using macroscopic observation, various microscopes, image analysis software, etc. When defining by area ratio, there is no limitation on which cross section or surface in the cell structure defines the area ratio, but for example, when the cell structure is a sphere, it may be defined by a cross section passing through the approximate center.

[0049] For example, when the collagen component in the cell structure is defined by the area ratio, the area ratio is 0.01 to 99% based on the total area of ​​the cell structure, preferably 1 to 99%, preferably 5 to 90%, preferably 7 to 90%, preferably 20 to 90%, and more preferably 50 to 90%. The "collagen component in the cell structure" is as described above. The area ratio of the collagen component constituting the cell structure means the combined area ratio of the endogenous collagen component and the exogenous collagen component. The area ratio of the collagen component can be calculated, for example, by staining the obtained cell structure with Masson's trichrome and calculating the ratio of the area of ​​the collagen component stained blue to the total area of ​​the cross section passing through the approximate center of the cell structure.

[0050] (First Cell) The first cells are cells that constitute the connective tissue structure in the cell structure according to this embodiment. The first cells include at least mesenchymal cells. Examples of mesenchymal cells include cells of connective tissue such as fibroblasts, bone cells, chondrocytes, osteoblasts, muscle cells, tendon cells, adipocytes, hair papilla cells, and dental pulp cells, as well as cells capable of differentiating into the above cells. From the viewpoint of secreting endogenous extracellular matrix components and further strengthening the binding strength of the connective tissue structure, the mesenchymal cells preferably include fibroblasts.

[0051] The content of mesenchymal cells may be, for example, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less, relative to the total number of cells in the connective tissue structure.

[0052] The cell structure according to the present embodiment is provided with a connective tissue structure containing fragmented extracellular matrix components and mesenchymal cells, and thus can exhibit, for example, high intercellular adhesion. As a result, the cell structure according to the present embodiment can be a structure that is closer to biological tissue.

[0053] The first cells may further include other cells other than mesenchymal cells. Examples of the other cells include vascular endothelial cells, cancer cells such as colon cancer cells (e.g., human colon cancer cells (HT29)), and hepatic cancer cells, cardiomyocytes, lymphatic endothelial cells, nerve cells, dendritic cells, hepatic cells, adhesive cells (e.g., immune cells), smooth muscle cells (e.g., aortic smooth muscle cells (Aorta-SMC)), pancreatic islet cells, and keratinocytes (e.g., human epidermal keratinocytes). The first cells may include vascular endothelial cells from the viewpoint of enabling the formation of a cell structure closer to a living tissue.

[0054] As used herein, the term "vascular endothelial cells" refers to flat cells that constitute the surface of the blood vessel lumen. Examples of vascular endothelial cells include human umbilical vein-derived vascular endothelial cells (HUVEC).

[0055] The content of vascular endothelial cells may be, for example, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more of the total number of cells in the connective tissue structure, and may be 95% or less, 90% or less, 80% or less, or 75% or less.

[0056] (vascular network between cells) When the first cells include vascular endothelial cells, the connective tissue structure can have a vascular network between the cells. The connective tissue structure preferably has a vascular network between the mesenchymal cells. "Having a vascular network between the cells" means having a structure in which branched blood vessels extend between the cells so as to surround the cells, similar to living tissue.

[0057] The cell structure according to the present embodiment is expected to be able to maintain a vascular network between cells like living tissue for a long period of time even if the cell structure is thick. Furthermore, a cell structure that can have a vascular network is expected to be more likely to take root when transplanted into a mammal or the like.

[0058] Whether or not a vascular network similar to that in living tissue is formed can be determined based on, for example, the number of vascular branches in the living tissue and / or the length between the vascular branches and / or the diversity of the vascular diameter. For example, when the average number of vascular branches in the cell structure is 80% or more and 150% or less, 85% or more and 130% or less, or 90% or more and 120% or less, it may be determined that the number of vascular branches in the cell structure is similar to that in the living tissue.

[0059] For example, when the average value of the number of branches of blood vessels in the connective tissue structure is 2.5 or more and 4.5 or less, or 3.0 or more and 4.2 or less, it may be determined that the number of branches of blood vessels in the connective tissue structure is similar to that in the biological tissue. For example, when the average value of the length between the branches of blood vessels in the connective tissue structure is 80% or more and 150% or less, 85% or more and 130% or less, or 90% or more and 120% or less, it may be determined that the length between the branches of blood vessels in the biological tissue is similar to that in the biological tissue. Both thick blood vessels and thin blood vessels are observed in the biological tissue. Therefore, for example, when both blood vessels with thick diameters (e.g., 10 μm or more and less than 25 μm) and blood vessels with thin diameters (e.g., more than 0 μm and less than 10 μm) are observed as in the biological tissue, it may be determined that the blood vessels have the same diversity as the blood vessel diameters in the biological tissue. In addition, when 60% or more, 70% or more, or 80% or more of the total blood vessel diameters are distributed in the range of more than 0 μm and less than 25 μm, it may be determined that the blood vessels have the same diversity as the blood vessel diameters in the biological tissue.

[0060] [Epithelial structure] The epithelial structure includes a second cell. The second cell is a cell that constitutes the epithelial structure in the cell structure according to this embodiment. The second cell includes at least an epithelial cell. An example of the epithelial cell is a human gingival epithelial cell. The epithelial cell may be, for example, an immortalized epithelial cell obtained by transformation of a human gingival epithelial cell.

[0061] The second cells may further include cells other than epithelial cells, such as vascular endothelial cells, adipocytes, colon cancer cells (e.g., human colon cancer cells (HT29)), hepatic cancer cells, and other cancer cells, cardiomyocytes, lymphatic endothelial cells, nerve cells, dendritic cells, hepatic cells, adhesive cells (e.g., immune cells), smooth muscle cells (e.g., aortic smooth muscle cells (Aorta-SMC)), pancreatic islet cells, and keratinocytes (e.g., human epidermal keratinocytes).

[0062] The epithelial cell content may be, for example, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less, relative to the total number of cells in the epithelial structure.

[0063] <Method of manufacturing cell structures> The method for producing a cell structure according to this embodiment includes a first step of forming a connective tissue structure by contacting fragmented extracellular matrix components with first cells, including mesenchymal cells, and culturing the first cells, and a second step of forming an epithelial structure on the connective tissue structure by contacting second cells, including epithelial cells, with the connective tissue structure and culturing the connective tissue structure and the second cells, thereby obtaining a cell structure.

[0064] [First step] In the first step, a connective tissue structure is formed by contacting the fragmented extracellular matrix components with first cells including mesenchymal cells (first contact step) and then culturing the first cells (first culture step).

[0065] The connective tissue structure comprises a fragmented extracellular matrix component and a first cell, the fragmented extracellular matrix component and the first cell may be as described above.

[0066] By dispersing the fragmented extracellular matrix components in an aqueous medium, they become more easily accessible to cells in the aqueous medium, and can promote the formation of a connective tissue structure.

[0067] (First Contact Step) The fragmented extracellular matrix component and the first cells may be contacted in an aqueous medium. Methods for contacting the fragmented extracellular matrix component and the first cells include, but are not limited to, a method of mixing an aqueous medium containing the fragmented extracellular matrix component with an aqueous medium containing the first cells, a method of adding the first cells to an aqueous medium containing the fragmented extracellular matrix component, a method of adding an aqueous medium containing the fragmented extracellular matrix component to a culture solution containing the first cells, a method of adding the first cells to an aqueous medium containing the fragmented extracellular matrix component, and a method of adding the fragmented extracellular matrix component and the first cells to a previously prepared aqueous medium.

[0068] The aqueous medium may be, for example, a liquid medium. The medium is not particularly limited, and a suitable medium can be selected depending on the type of cells to be cultured. Examples of the medium include Eagle's MEM medium, DMEM, Modified Eagle medium (MEM), Minimum Essential medium, RPMI, and GlutaMax medium. The medium may be a medium containing serum or a serum-free medium. The medium may be a mixed medium in which two types of media are mixed.

[0069] The contact between the fragmented extracellular matrix component and the first cells may be performed after forming a layer of the first cells in an aqueous medium. That is, the first contacting step may be performed by forming a layer of the first cells in an aqueous medium and then contacting the fragmented extracellular matrix component. By forming a layer of the first cells before contacting the layer with the extracellular matrix component, a connective tissue structure having a high cell density in the lower layer can be prepared.

[0070] The fragmented extracellular matrix components can be obtained by the above-mentioned method. The fragmented extracellular matrix components may be obtained by fragmenting the extracellular matrix components in an aqueous medium. That is, the production method according to this embodiment may include a step of fragmenting the extracellular matrix components in an aqueous medium (fragmentation step) prior to the first step. The aqueous medium may be the same as the aqueous medium containing the fragmented extracellular matrix components described above.

[0071] The fragmented extracellular matrix component may be any of those exemplified above, and may include a fragmented collagen component.

[0072] The manufacturing method according to this embodiment may include a step of heating the extracellular matrix components before the fragmentation step to crosslink at least a portion of the extracellular matrix components, or may include a step of heating the extracellular matrix components after the fragmentation step and before the contacting step to crosslink at least a portion of the extracellular matrix components.

[0073] In the crosslinking step, the temperature (heating temperature) and time (heating time) when heating the extracellular matrix component can be appropriately determined. The heating temperature may be, for example, 100°C or higher, 200°C or lower, or 220°C or lower. Specifically, the heating temperature may be, for example, 100°C, 110°C, 120°C, 130°C, 140°C, 150°C, 160°C, 170°C, 180°C, 190°C, 200°C, 220°C, etc. The heating time (the time to hold at the above heating temperature) can be appropriately set depending on the heating temperature. For example, when heating at 100°C to 200°C, the heating time may be 6 hours or more and 72 hours or less, more preferably 24 hours or more and 48 hours or less. In the crosslinking step, heating may be performed in the absence of a solvent, or under reduced pressure conditions.

[0074] The production method according to this embodiment may include a drying step of drying the fragmented extracellular matrix components after the fragmentation step.

[0075] In the drying step, the fragmented extracellular matrix components are dried. Drying may be performed, for example, by freeze-drying. By performing the drying step after the fragmentation step, the aqueous medium is removed from a liquid containing the fragmented extracellular matrix components and the aqueous medium. Removal of the aqueous medium does not mean that no moisture is attached to the fragmented extracellular matrix components, but means that moisture is not attached to a degree that can be reasonably achieved by the above-mentioned general drying method.

[0076] The content of mesenchymal cells may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less, relative to the total number of the first cells in the first contact step.

[0077] In the first contact step, the first cells preferably further comprise vascular endothelial cells. By using the first cells further comprising vascular endothelial cells and the fragmented extracellular matrix components, a connective tissue structure having a vascular network between the cells can be formed.

[0078] The content of vascular endothelial cells may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less, relative to the total cell number of the first cells in the first contact step.

[0079] The ratio of the cell numbers of mesenchymal cells to vascular endothelial cells (mesenchymal cells / vascular endothelial cells) is not particularly limited and may be, for example, 100 / 1 to 1 / 100, 50 / 1 to 1 / 50, 20 / 1 to 1 / 1, 10 / 1 to 1 / 1, 8 / 1 to 1 / 1, 7 / 1 to 1.2 / 1, 6 / 1 to 1.5 / 1, 5 / 1 to 2 / 1, or 3 / 1 to 2 / 1.

[0080] The concentration of the extracellular matrix components in the first contact step can be appropriately determined depending on the shape and thickness of the desired connective tissue structure, the shape and thickness of the cell structure, the size of the culture vessel, etc. For example, the concentration of the extracellular matrix components in the aqueous medium in the first contact step may be 0.1 to 90% by mass, or 1 to 30% by mass.

[0081] The amount of fragmented extracellular matrix components to be contacted with the first cells is, for example, 1.0×10 6 For cells, the amount may be 0.1 to 100 mg, 0.5 to 50 mg, 0.8 to 25 mg, 1.0 to 10 mg, 1.0 to 5.0 mg, 1.0 to 2.0 mg, or 1.0 to 1.8 mg, and may be 0.7 mg or more, 1.1 mg or more, 1.2 mg or more, 1.3 mg or more, or 1.4 mg or more, and may be 7.0 mg or less, 3.0 mg or less, 2.3 mg or less, 1.8 mg or less, 1.7 mg or less, 1.6 mg or less, or 1.5 mg or less.

[0082] In the first contact step, the mass ratio of the fragmented extracellular matrix components to the first cells (extracellular matrix components / cells) is preferably 1 / 1 to 1000 / 1, more preferably 9 / 1 to 900 / 1, and even more preferably 10 / 1 to 500 / 1.

[0083] (First culture step) The method for culturing the first cells is not particularly limited, and can be a suitable culturing method depending on the type of cells to be cultured. For example, the culture temperature may be 20°C to 40°C, or 30°C to 37°C. The pH of the medium may be 6 to 8, or 7.2 to 7.4. The culture time may be 1 day to 2 weeks, or 1 week to 2 weeks.

[0084] The cell density in the medium in the first culture step can be appropriately determined depending on the shape and thickness of the desired connective tissue structure, the size of the culture vessel, etc. For example, the cell density in the medium in the first culture step can be 1 to 10 8 cells / mL,3 ~10 7 The cell density in the medium in the first culture step may be the same as the cell density in the aqueous medium in the first contact step.

[0085] The method may further include a step of precipitating the extracellular matrix components and the first cells in the aqueous medium after the first contact step and before the first culture step. By carrying out such a step, the distribution of the extracellular matrix components and the cells in the connective tissue structure becomes more uniform. There are no particular limitations on the specific method, but an example of the method is a method of centrifuging a culture solution containing the extracellular matrix components and the cells.

[0086] [Second step] In the second contact step, second cells including epithelial cells are contacted with the connective tissue structure (second contact step), and the connective tissue structure and the second cells are cultured (second culture step), thereby forming an epithelial structure on the connective tissue structure and obtaining a cell structure.

[0087] Before contacting the connective tissue structure with the second cells including epithelial cells, the connective tissue structure may be contacted with collagen (e.g., type IV collagen) as necessary. In this case, a cell structure in which an epithelial structure is arranged on the connective tissue structure is more likely to be formed. For example, collagen can be contacted with the connective tissue structure by holding the connective tissue structure in a solution containing collagen (collagen solution). The connective tissue structure may be held in the collagen solution at, for example, 37°C for 20 minutes or more. The collagen concentration in the collagen solution may be, for example, 0.01 to 0.10 mg / mL or 0.02 to 0.06 mg / mL.

[0088] The connective tissue structure and the second cells may be contacted in an aqueous medium. Methods for contacting the connective tissue structure and the second cells include, but are not limited to, a method of mixing an aqueous medium containing a connective tissue structure with an aqueous medium containing the second cells, a method of adding the second cells to an aqueous medium containing a connective tissue structure, a method of adding an aqueous medium containing a connective tissue structure to a culture solution containing the second cells, a method of adding the second cells to an aqueous medium containing a connective tissue structure, and a method of adding the connective tissue structure and the cells to a previously prepared aqueous medium.

[0089] The aqueous medium may be, for example, a liquid medium. The medium is not particularly limited, and a suitable medium can be selected depending on the type of cells to be cultured. The medium may be the same type of medium as that used in the first step, or a different type of medium. Examples of the medium include Eagle's MEM medium, DMEM, Modified Eagle medium (MEM), Minimum Essential medium, RPMI, and GlutaMax medium. The medium may be a medium supplemented with serum or a serum-free medium. The medium may be a mixed medium in which two types of media are mixed.

[0090] In the second contact step, the content of epithelial cells may be 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more, and may be 95% or less, 90% or less, 80% or less, or 75% or less, relative to the total cell number of the second cells.

[0091] (Second culture step) The method for culturing the connective tissue structure and the second cell is not particularly limited, and can be a suitable culture method depending on the type of cell to be cultured. For example, the culture temperature can be 20°C to 40°C, or 30°C to 37°C. The pH of the medium can be 6 to 8, or 7.2 to 7.4. The culture time can be 1 day to 2 weeks, or 1 week to 2 weeks.

[0092] The medium is not particularly limited, and a suitable medium can be selected depending on the type of cells to be cultured. The medium may be, for example, the medium described above.

[0093] The cell density in the medium in the second culture step can be appropriately determined depending on the shape and thickness of the desired cell structure, the size of the culture vessel, etc. For example, the cell density in the medium in the second culture step can be determined in the range of 1 to 10 8 cells / mL, 3 ~10 7 The cell density in the medium in the second culture step may be the same as the cell density in the aqueous medium in the second contact step.

[0094] The cell structure produced by the production method according to this embodiment preferably has a shrinkage rate during culture of 20% or less, more preferably 15% or less, and even more preferably 10% or less. The shrinkage rate can be calculated, for example, by the following formula. In the formula, L1 represents the length of the longest part of the cell structure on the first day after culture, and L3 represents the length of the corresponding part of the cell structure on the third day after culture. Shrinkage rate (%) = {(L1-L3) / L1} x 100

[0095] In the above example, the contraction rate is calculated from the cell structure on day 1 after culture and the cell structure on day 3 after culture, but it may be calculated from the cell structure at any time point during the culture period, including the end of the culture. For example, it may be calculated from the cell structure on day 1 after culture and the cell structure on day 2 after culture, from the cell structure on day 1 after culture and the cell structure on day 5 after culture, or from the cell structure on day 1 after culture and the cell structure on day 8 after culture.

[0096] After the second culture step, the method may further include a step of contacting a third cell and a step of culturing the third cell. The third cell may be the same type as the above-mentioned cell or may be a different type. This allows a three-layered cell structure to be produced. Furthermore, by repeatedly including the contact step and the culture step, a multi-layered cell structure can be produced, and a tissue closer to a more complex living organism can be produced.

[0097] The method may further include a step of precipitating the connective tissue structure and the second cells in the aqueous medium after the second contact step and before the second culture step. By carrying out such a step, the distribution of the extracellular matrix components and the cells in the cell structure becomes more uniform. There is no particular limitation on the specific method, but an example of the method is a method of centrifuging the culture solution containing the connective tissue structure and the second cells.

[0098] <Applications of cell structures> The cell structure according to the present embodiment can be used for transplantation, for example. The cell structure according to the present embodiment can have a vascular network between cells like living tissue. This is expected to facilitate engraftment when transplanted into animals such as mammals.

[0099] The animal to be transplanted is not particularly limited, and may be, for example, a mammal, a human, or a non-human animal such as a monkey, a dog, a cat, a rabbit, a pig, a cow, a mouse, or a rat.

[0100] The transplantation method according to this embodiment includes transplanting the cell structure according to this embodiment into an animal. Prior to the transplantation, the method may further include preparing the animal to be transplanted and / or preparing the cell structure by the above-mentioned method. The transplantation method is not particularly limited, and may be carried out by a known surgical method or the like as appropriate according to the transplantation target, etc. The cell structure according to this embodiment can be applied to tissue reconstruction, for example.

[0101] The method for producing a non-human model animal according to the present embodiment includes transplanting the cell structure according to the present embodiment into a non-human animal. Before the transplantation, the method may further include preparing a non-human animal to be transplanted and / or producing a cell structure by the above-mentioned method. The non-human model animal according to the present embodiment can be used to apply data obtained from animal experiments to humans. In order to produce a non-human model animal, it is preferable to use a non-human animal in which rejection of a transplant (graft) is suppressed, for example, a non-human animal with reduced or impaired immunity.

[0102] The cell structure of this embodiment itself can be used as a substitute for experimental animals, transplant materials, etc., and specific examples of its application include tissue reconstruction, pathological in vitro models, screening of pharmaceuticals, cosmetics, or medicinal cosmetics (evaluation of drugs), assay screening of pharmaceuticals, cosmetics, or medicinal cosmetics, etc., as described above.

[0103] <Bacteria-containing tissue model> Since the cell structure of this embodiment is closer to biological tissue, by placing bacteria in the cell structure, it can be suitably used as a tissue model for evaluating the behavior of bacteria in biological tissue (e.g., bacterial survival and / or infiltration) and / or the effect of bacteria on the cell structure (e.g., the behavior of cells located around cells in contact with bacteria in the cell structure).

[0104] As one embodiment of the present invention, a bacteria-containing tissue model is provided comprising a cell structure according to this embodiment and bacteria arranged inside the cell structure or in contact with an epithelial structure of the cell structure.

[0105] The bacteria are not particularly limited as long as they can adhere to tissues such as gums, oral cavity, skin, and cornea and act on the tissues. Specific examples of bacteria include periodontal disease bacteria, oral bacteria, and the like. For example, when the bacteria is periodontal disease bacteria, the bacteria-containing tissue model can also be used as a model for evaluating periodontal disease bacteria. Examples of periodontal disease bacteria include Prophyromonas gingivalis, Treponema denticola, Prevotella intermedia, Aggregatibacter actinomycetemcomitans, Actinobacicclus actino-mycetemcomitans, and Bacteroides forsythus.

[0106] <Method of manufacturing bacteria-containing tissue model> The method for producing a bacteria-containing tissue model according to this embodiment includes a step of contacting bacteria with the epithelial structure of the cell structure described above.

[0107] The method for producing the bacteria-containing tissue model may further include a step of culturing the cell structure and the bacteria and transferring the bacteria to the inside of the cell structure after the step of contacting the bacteria. In the transferring step, the bacteria may be transferred to the inside of the epithelial structure of the cell structure and / or the inside of the connective tissue structure of the cell structure.

[0108] Methods for assessing the behavior of cell structures and / or bacteria As one embodiment of the present invention, there is provided a method for evaluating the behavior of a cell structure and / or bacteria, comprising a step (evaluation step) of contacting bacteria with the epithelial structure of the cell structure described above and then evaluating the behavior of the cell structure and / or bacteria. The method may include a step (contact step) of contacting bacteria with the epithelial structure of the cell structure described above before the evaluation step.

[0109] In the method for evaluating the behavior of a cell structure and / or bacteria, the evaluation step and / or the contact step may be performed in the presence of a chemical substance (e.g., a pharmaceutical agent). For example, the evaluation step may be performed in an environment where the cell structure is exposed to a pharmaceutical agent or the like, or in an environment where a pharmaceutical agent or the like is administered to the cell structure. In the evaluation step, the effect on cells located around the cells contacted with the bacteria may be evaluated. In the evaluation step, the engraftment and / or invasion of the bacteria may be evaluated. For example, in the evaluation step, the route by which the bacteria invade the cell structure may be evaluated.

[0110] The evaluation step can be carried out, for example, by comparing the cell structure and / or bacteria immediately after contacting the bacteria with the epithelial structure of the cell structure with the cell structure and / or bacteria after a predetermined time (for example, 1 to 72 hours, 2 to 48 hours, 2 to 24 hours, 3 to 8 hours, or 4 to 6 hours) has elapsed since contacting the bacteria. For example, by staining nucleic acid contained in the bacteria, obtaining a cross-sectional image of the cell structure contacted with the bacteria, and comparing the obtained cross-sectional images, it is possible to evaluate whether the bacteria have migrated inside the cell structure. By the evaluation method according to this embodiment, it is possible to evaluate, for example, whether the bacteria have migrated inside the epithelial structure or connective tissue structure, or into the vascular network of the cell structure.

[0111] In the evaluation step, for example, the amount of inflammatory cytokines secreted from the cell structure can be evaluated as the behavior of the cell structure. The inflammatory cytokine may be, for example, interleukin-6 (IL-6). As a method for evaluating the amount of inflammatory cytokines, for example, the method described in the Examples below can be used. EXAMPLES

[0112] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.

[0113] <Test Example 1: Preparation of defibrated collagen component> A freeze-dried type I collagen derived from pig skin (manufactured by Nippon Ham Co., Ltd.) was dispersed in 10-fold concentrated phosphate buffered saline (x10 PBS) to prepare a type I collagen dispersion. The type I collagen dispersion was homogenized for 5 minutes using a homogenizer to obtain defibrated collagen (hereinafter also referred to as "CMF"). The average length of the obtained CMF was 22.5 μm, and the average diameter was about 4.4 μm.

[0114] The longitudinal and transverse lengths of the CMFs were determined by analyzing each CMF with an electron microscope. The average length and diameter are the average values ​​measured for 391 samples.

[0115] The obtained CMF was washed with serum-free medium (DMEM) to obtain a medium dispersion of CMF. The obtained medium dispersion of CMF could be stored at room temperature for one week. The CMF used in the examples described below was obtained by the same method.

[0116] <Test Example 2: Preparation of cell structure> The cells, reagents and preparation method used in preparing the cell structures are as follows. · Immortalized human gingival epithelial cells (Epi4) Culture medium: Humedia-KG2 (KURABO KK2150S) ·Human gingival fibroblasts (HGF) ·Medium: DMEM 10% FBS p / s Human umbilical vein-derived endothelial cells (HUVEC): CC-2517 (manufactured by Lonza) Culture medium: EGM2MV (Lonza CC-3202) Gingivalis: ATCC 33277 Culture medium: 5% sheep blood agar (Becton Dickinson, 252201) · Protease-deficient strain of Gingivalis: Gene knockdown of ATCC strain ·Anti-CD31 antibody (Dako, m0823) DAPI (Invitrogen 62248) Alexa Fluor 647 phalloidin (Invitrogen A22287) ·Anti-Prophyromonas gingivlis (P.gingivlis) antibody

[0117] Gingival epithelial cells (Epi4), HGF, and a protease-deficient strain of P. gingivalis (ATCC) (gene knockdown of the ATCC strain) were provided by the Osaka University School of Dentistry. All preculture of cells was performed according to standard procedures.

[0118] (Preparation of connective tissue constructs) 4 mg of type I collagen derived from pig skin (disintegrated by homogenization for 5 minutes) manufactured by Nippon Ham Co., Ltd. and 1.0 × 10 normal human gingival fibroblasts (HGF) were used. 6 cells and HUVECs 5.0 × 10 5 The cells were suspended in a mixed medium of D-MEM (Wako Pure Chemical Industries, Ltd.) and EGM2MV mixed at a ratio of 1:1, and the resulting suspension was added to a 24-well insert (Corning Incorporated), and the mixed medium was added to the outside of the insert and cultured overnight. This produced a connective tissue construct. After that, the medium was changed every day and cultured.

[0119] (Preparation of epithelial structures) Seven days after the formation of the connective tissue construct, the medium on the insert was aspirated, the surface of the connective tissue construct was coated with 0.04 mg / mL collagen type IV (Sigma-Aldrich), and immortalized human gingival epithelial cells (Epi4) were added at 1.0 × 10 6 The concentration was adjusted to 300μl / insert and Epi4 was seeded on the connective tissue construct. 1ml of a mixed medium made by mixing D-MEM, EGM2MV and Humedia (Kurashiki Boseki Co., Ltd.) in a 1:1:1 ratio was placed on the outside of the insert and incubated at 37°C for 1 hour, after which 1mL of the mixed medium was added to the outside of the insert and cultured overnight. This produced a cell construct equipped with a connective tissue construct and an epithelial construct. This cell construct was used as a cell construct for the engraftment and invasion evaluation described below.

[0120] After seeding Epi4 and culturing for one day, the cell construct was fixed with paraformaldehyde, sliced, and stained with hematoxylin and eosin (HE). The results of the observation of the cell construct by HE staining are shown in Figure 1. It was confirmed that the fabricated cell construct consisted of a connective tissue construct (Figure 1a) and an epithelial construct placed on the connective tissue construct (Figure 1b). No tissue contraction or cracking was observed in the fabricated cell construct.

[0121] It was confirmed that CMFs were arranged between the cells in the connective tissue structure of the cell construct that was created. Immunostaining with anti-CD31 antibody (Dako) confirmed the formation of a vascular network in the connective tissue structure of the cell construct that was created (Figure 2).

[0122] <Test Example 3: Preparation of cell structure and invasion evaluation> The cell structure for evaluation was obtained in the same manner as in Test Example 2, except that the cell structure did not contain HUVECs (HUVECs were not used in forming the connective tissue structure). 7 P. gingivalis cells were cultured on an agar medium, detached from the medium, suspended in the same mixed medium used to prepare the epithelial structures, but without antibiotics, and seeded on the epithelial structures.

[0123] The results of observation of the evaluation constructs immediately after the bacteria were seeded and 4 hours after the seeding (post-infection) are shown in Figure 3. Figure 3(a) shows the connective tissue construct, and Figure 3(b) shows the epithelial construct. The arrows in Figure 3(B) indicate the bacteria. The scale bar in Figure 3 indicates 50 μm.

[0124] As shown in FIG. 3, bacteria were shown to migrate into connective tissue and epithelial structures.

[0125] <Test Example 4: Confirmation of engraftment and invasion of P. gingivalis> A cell structure for evaluation was used, which was obtained in the same manner as in Test Example 2, except that the cell structure did not contain HUVECs (HUVECs were not used when forming the connective tissue structure). The seeding amount for the cell structure for evaluation was 2.4 × 10 7 P. gingivalis was inoculated in the same manner as described in Test Example 3, except that cells were used.

[0126] The cell structures were detached from the inserts 24 and 48 hours after inoculation with P. gingivalis, and DNA extraction and real-time PCR were performed. DNA extraction was performed using Zymo research R2081 according to the instructions. Real-time PCR was performed using a kit (THUNDERBIRDR Probe qPCR RT Set (TOYOBO)) according to the instructions.

[0127] Two types of P. gingivalis were used: the wild type and a mutant type lacking protease (Δkpg rgpA rgpB). The results are shown in Table 1. "ND" in Table 1 indicates that it was not detected.

[0128] In vivo, gingival tissue has barrier properties due to strong adhesion between cells, and it is known that in order for periodontal disease bacteria (P. gingivalis) to invade gingival tissue, proteins that contribute to intercellular adhesion must be decomposed by proteases. According to the results of this study, as shown in Table 1, when protease-deficient periodontal disease bacteria were used, the number of invaded bacteria was significantly reduced. This demonstrated that protease expression is necessary for periodontal disease bacteria to effectively invade cell structures created using CMF, and also demonstrated that cell structures created using CMF are tissue models that are closer to living organisms.

[0129] [Table 1]

[0130] <Test Example 5: Confirmation of adhesion factor expression state (qRT-PCR)> A cell structure for evaluation obtained in the same manner as described in Test Example 2, except that the cell structure did not contain HUVECs (HUVECs were not used when forming the connective tissue structure), was used as a sample with CMF.

[0131] The cell structure for evaluation obtained in the same manner as described in Test Example 2, except that no CMF was used and that the cell structure did not contain HUVEC (HUVEC were not used when forming the connective tissue structure), was used as a sample without CMF.

[0132] After seeding Epi4, the cell construct was cultured for one day and then detached from the insert, and mRNA extraction and real-time PCR were performed. TM The RNA Mini Kit was used according to the instructions. Real-time PCR was performed using a kit (SYBR Green Realtime PCR Master Mix (TOYOBO)) according to the instructions.

[0133] The results of confirming the expression of adhesion factors are shown in Table 2. As shown in Table 2, when CMF was used, the expression level of adhesion factors was higher than when CMF was not used, indicating that the gingival model was closer to the living body. *1 indicates 0.00004596, and 0 *2 indicates 0.000008649, and 0 *3 shows 0.0000406.

[0134] [Table 2]

[0135] <Test Example 6: Preparation of cell structure having vascular network> 1. Preparation of type I collagen solution (10 mg / mL) 50 mg of freeze-dried pig skin-derived type I collagen (provided by Nippon Ham Co., Ltd.) was taken into a centrifuge tube, 5 mL of 10xPBS (pH 7.4) was added, and homogenized for 6 minutes. The mixture was centrifuged at 10,000 rpm for 3 minutes, pipetted and vortexed, and then centrifuged again at 10,000 rpm for 3 minutes. After aspirating the supernatant, 5 mL of DMEM (serum-free) was added, the precipitate was firmly pipetted, and centrifuged at 10,000 rpm for 3 minutes. The supernatant was then aspirated and DMEM containing 8% FBS was added so that the homogenized type I collagen content was 10 mg / mL. After suspension, the required amount was taken into an Eppendorf tube. The average length of the obtained defibrated collagen (CMF) was 22.5 μm, and the average diameter was approximately 4.4 μm.

[0136] 2. Construction of a connective tissue structure (connective tissue layer) with a vascular network HGF (1.0 × 10 6 cells / tissue and HUVECs (5.0 × 10 5 A 24-well insert was mixed with a type I collagen solution containing 10 mg / mL of 100 cells / tissue and type I collagen, and seeded onto the insert. 0.5 mL of 8% FBS / DMEM and EGM-2 (Lonza) mixed medium (1:1) was added to the outside of the insert, and the insert was centrifuged at 1100xg for 15 minutes and cultured at 37°C. The next day, the 24-well insert was transferred to a 6-well plate and cultured for one week in 12 mL of 8% FBS-containing DMEM and EGM-2 mixed medium (1:1).

[0137] 3. Construction of epithelial structure (epithelial cell layer) The medium inside the insert of the connective tissue construct was aspirated, and PBS containing type IV collagen at a concentration of 0.04 mg / mL (type IV collagen solution) was added to the inside of the insert, and incubated at 37°C for 20 minutes or more. During this time, a cell suspension of IHGE cells was prepared using a mixture of 8% FBS-containing DMEM:EGM-2:2% FBS-containing HuMedia-KG2 (Kurabo) = 1:1:1. After aspirating the type IV collagen solution inside the insert and the outside medium, epithelial cells were seeded on the inside, mixed medium was added to the outside, and the insert was left to stand for 1 hour at 37°C. Then, mixed medium was added to the outside, and in the case of a 24-well insert, the inside and outside were connected and cultured overnight. This resulted in the construction of a gingival model tissue consisting of a cell structure in which an epithelial structure was placed on a connective tissue construct.

[0138] 4. Cultivation of P. gingivalis P. gingivalis ATCC 33277 was inoculated onto blood agar (BD) and maintained under anaerobic conditions at 37°C. Growth to the logarithmic growth phase was achieved using trypticase soy broth (TBS) medium (BD) supplemented with heamin (5 μg / mL, Sigma-Aldrich) and menadione (1 μg / mL, Sigma-Aldrich).

[0139] 5. Infection with P. gingivalis 2.4x10 P. gingivalis 7 The ratio of cells / tissue was adjusted to 1:1:1 with antibiotic-free 8% FBS-containing DMEM:EGM-2:2% FBS-containing HuMedia-KG2 (Kurabo) mixed medium, and administered to the gingival model tissue. After administration, the cells were cultured in a 37℃ 5% CO2 incubator.

[0140] 6. Immunohistochemical analysis of P. gingivalis Sections of P. gingivalis-infected gingival model tissue were incubated overnight at 4°C with anti-P. gingivalis antibody produced in rabbit (Sigma-Aldrich). Then, they were treated with horse radish peroxidase conjugated goat anti-rabbit IgG (Nichirei Biosciences, Inc.) and stained with 3,3'-diaminobenzidine substrate solution (DAKO). Haematoxylin was used for counterstaining.

[0141] 7. P. gingivalis invasion assay P. gingivalis was stained using the Bacstain-CTC Rapid Staining kit (Dojindo Laboratories, Inc.). P. gingivalis was suspended in PBS, and the suspension was incubated with 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) and Enhancing reagent B at 37°C for 30 minutes. After washing the gingival model tissue with PBS, the stained P. gingivalis was administered to the gingival model tissue, and co-cultured in a 5% CO2 incubator at 37°C.

[0142] P. gingivalis was labeled with a fluorescent dye before administration to the gingival model tissue. The -Bacstain-CTC Rapid Staining Kit (for Microscopy) was used for labeling. This kit detects NAD(P)H generated within cells by electron transfer, which represents respiratory activity. CTC is reduced by this NAD(P)H to fluorescent formazan (λex = around 430, 480 nm, λem = 620-640 nm). This fluorescent formazan is observed by depositing in the cells, making it possible to observe individual cells. The enhancer included in the kit promotes the reduction reaction of CTC by NAD(P)H, enabling highly sensitive detection.

[0143] Figure 4 shows images of P. gingivalis labeled with anti-CD31 antibody and CTC. Figure 4 shows that P. gingivalis colocalized with the vascular network structure. The photographs shown in Figure 4 reveal that P. gingivalis was able to invade the vascular network structure of the gingival model tissue. A colocalization signal was also observed in the gingival model tissue infected with a cell line (P. gingivalis ΔkgpΔrgpAΔrgpB) that lacks gingipain, an enzyme with trypsin-like activity, but the signal level was lower than that of the model infected with P. gingivalis WT. The above results suggest that gingipain is likely involved in the migration of P. gingivalis into the deeper parts of the gingival tissue and the invasion of capillaries.

[0144] In addition to the image shown in Figure 4, two similar images were taken (a total of three images), and the area values ​​of the regions where P. gingivalis colocalized with the vascular network structure were analyzed using Image J, and the average values ​​were calculated. The calculation results are shown in Figure 5. As shown in Figure 5, similar to the results confirmed from the images in Figure 4, it was confirmed that P. gingivalis had infiltrated into the vascular network. Infiltration of P. gingivalis into the vascular network was more pronounced in the WT than in the gingipain-deficient strain. In Figure 5, * indicates a significant difference (p<0.05).

[0145] Figure 6 shows the results of quantitative evaluation of the number of P. gingivalis infiltrating into the gingival model tissue. The number of P. gingivalis in the gingival model tissue after "5. Infection with P. gingivalis" in Test Example 6 was measured by real-time PCR. Real-time PCR was performed in the same manner as in Test Example 4. * indicates a significant difference (p<0.05).

[0146] FIG. 7 shows the evaluation results of the amount of IL-6 secreted after infection with P. gingivalis. The amount of IL-6 secreted from the gingival model tissue after "5. Infection with P. gingivalis" in Test Example 6 was measured and compared. IL-6 is a cytokine that is generally used as an indicator of inflammation. Generally, an increase in the amount of IL-6 indicates the occurrence of inflammation, i.e., infection.

[0147] According to the graph shown in Figure 7, the amount of IL-6 was lower in the WT-inoculated cells compared to the cells not inoculated with P. gingivalis and the gingipain-deficient strain, which is believed to be due to the gingipain-degrading effect of IL-6. The gingipain-deficient strain had higher IL-6 than the cells not inoculated with P. gingivalis, which, taken together with the data shown in Figure 4 and the quantitative evaluation results of the number of P. gingivalis shown in Figure 6, indicates that infection has occurred.

[0148] IL-6 was quantified by ELISA. After infecting gingival model tissue with P. gingivalis, the culture supernatant was collected 6, 24, and 48 hours later, and the amount of IL-6 in the culture supernatant was measured using ELISA MAX kits (BioLegend) according to the manual. In Figure 7, * indicates a significant difference (p<0.05).

[0149] 8 to 9 are diagrams showing the method for observing the behavior of P. gingivalis penetrating an epithelial cell layer and the observation results.

[0150] In vivo, P. gingivalis needs to penetrate the epithelial cell layer to migrate from the surface of gingival tissue to the connective tissue layer. It is known that some bacteria interact with lipid rafts to facilitate invasion of host cells. The following experiments confirmed that lipid rafts may be involved in the penetration of P. gingivalis into the epithelial cell layer and that P. gingivalis may migrate intracellularly, rather than intercellularly, as a primary route for migration to deeper regions of gingival tissue.

[0151] Figure 8 shows a method for observing the behavior of P. gingivalis penetrating an epithelial cell layer, using methyl-β-cyclodextrin (MβCD), a substance that can reversibly remove cholesterol from the plasma membrane of cells.

[0152] First, 1.0×10 6 IHGE cells were seeded into a 24-well plate transwell (Corning) with a porosity of 3 μm and cultured for one day in Humedia-KG2 medium to produce an epithelial structure (epithelial cell layer tissue) consisting only of the epithelial cell layer (Figure 8A).

[0153] Next, MβCD was dissolved in dimethyl sulfoxide (DMSO) to obtain an MβCD solution with a final concentration of 50 mM or 100 mM. The above MβCD solution was then mixed with Humedia-KG2 medium (final concentration of MβCD in the medium: 0.5 mM or 1.0 mM). After washing the epithelial cell layer tissue with PBS, the above Humedia-KG2 medium containing MβCD was added to the epithelial cell layer tissue in the transwell, and the epithelial cell layer tissue was incubated in Humedia-KG2 medium at 37°C for 30 minutes.

[0154] Next, CTC-labeled P. gingivalis was prepared by the same procedure as above, and the epithelial cell layer tissue was infected with CTC-labeled P. gingivalis (B in FIG. 8). After infection, the tissue was incubated at 37°C in Humedia-KG2 medium containing MβCD, and 24 and 48 hours after infection, the amount of CTC-labeled P. gingivalis that had penetrated the epithelial cell layer tissue from the upper transwell to the lower 24-well plate was analyzed using a spectrofluorometer FP-8500 (JASCO) (C in FIG. 8). The analysis results are shown in FIG. 9.

[0155] The amount of P. gingivalis infiltrated into the epithelial cell layer tissue treated with MβCD was significantly increased compared to the untreated tissue. This effect was confirmed to be stronger in a concentration-dependent manner. These results indicate that lipid rafts are involved in the migration of P. gingivalis through the epithelial cell layer. They also suggest that P. gingivalis may use the intracellular pathway, rather than the intercellular pathway, as the primary route for migration to deeper regions of gingival tissue.

Claims

1. A cell structure including a connective tissue structure and an epithelial structure disposed on the connective tissue structure, and a bacterium disposed inside the cell structure or in contact with the epithelial structure of the cell structure, the connective tissue structure comprises fragmented extracellular matrix components and first cells comprising mesenchymal cells; at least a portion of the fragmented extracellular matrix component is disposed between the first cells; the epithelial structure comprises epithelial cells; The average length of the fragmented extracellular matrix component is 100 nm or more and 200 μm or less, A bacteria-containing gingival model, wherein the content of the fragmented extracellular matrix components is 0.1 to 100 mg per 1.0×10 6 cells of the first cells.

2. The bacteria-containing gingival model according to claim 1 , wherein the mesenchymal cells include fibroblasts.

3. The bacteria-containing gingival model of claim 1 or 2, wherein the fragmented extracellular matrix component comprises a fragmented collagen component.

4. the first cells further comprise vascular endothelial cells; The bacteria-containing gingival model according to any one of claims 1 to 3, wherein the connective tissue structure has a vascular network among the first cells.

5. The bacteria-containing gingival model according to claim 4 , wherein the connective tissue structure has a vascular network between the mesenchymal cells.

6. The bacteria-containing gingiva model according to any one of claims 1 to 5, wherein the bacteria are periodontal bacteria.

7. A first step of forming a connective tissue structure by contacting fragmented extracellular matrix components with first cells including mesenchymal cells and culturing the first cells; a second step of contacting the connective tissue structure with second cells including epithelial cells and culturing the connective tissue structure and the second cells to form an epithelial structure on the connective tissue structure to obtain a cell structure; and contacting the epithelial structure of the cell structure with bacteria; The average length of the fragmented extracellular matrix component is 100 nm or more and 200 μm or less, A method for producing a bacteria-containing gingival model, wherein the amount of the fragmented extracellular matrix components to be contacted with the first cells is 0.1 to 100 mg per 1.0×10 6 cells.

8. The method for producing a bacteria-containing gingival model according to claim 7 , wherein the first cells include vascular endothelial cells.

9. The method for producing a bacteria-containing gingival model according to claim 7 or 8, further comprising the step of culturing the cell structure and bacteria after the step of contacting the bacteria, and transferring the bacteria to the inside of the cell structure.

10. A method for evaluating the behavior of a cell structure and / or bacteria using a bacteria-containing gingival model described in any one of claims 1 to 6, comprising a step of contacting bacteria with an epithelial structure of a cell structure and then evaluating the behavior of the cell structure and / or the bacteria.

Images